NASDAQ:NVAX

Novavax Stock Forecast, Price & News

$226.00
-11.54 (-4.86 %)
(As of 09/20/2021 04:20 PM ET)
Add
Compare
Today's Range
$220.25
$233.38
50-Day Range
$177.80
$270.58
52-Week Range
$76.59
$331.68
Volume105,501 shs
Average Volume4.43 million shs
Market Capitalization$16.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.62
30 days | 90 days | 365 days | Advanced Chart
Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.


Novavax logo

About Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

647th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

103rd out of 193 stocks

Analyst Opinion: 2.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Novavax (NASDAQ:NVAX) Frequently Asked Questions

Is Novavax a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax
or view top-rated stocks.

What stocks does MarketBeat like better than Novavax?

Wall Street analysts have given Novavax a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novavax wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Novavax?

Novavax saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 7,180,000 shares, an increase of 21.9% from the July 29th total of 5,890,000 shares. Based on an average daily volume of 4,960,000 shares, the days-to-cover ratio is presently 1.4 days. Currently, 9.8% of the company's stock are sold short.
View Novavax's Short Interest
.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Novavax
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) posted its earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($4.75) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($3.63) by $1.12. The biopharmaceutical company earned $298.02 million during the quarter, compared to the consensus estimate of $370.80 million. Novavax had a negative net margin of 80.37% and a negative trailing twelve-month return on equity of 150.88%. During the same period last year, the business posted ($0.30) EPS.
View Novavax's earnings history
.

How has Novavax's stock price been impacted by Coronavirus?

Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVAX stock has increased by 2,057.1% and is now trading at $226.71.
View which stocks have been most impacted by COVID-19
.

When did Novavax's stock split? How did Novavax's stock split work?

Novavax shares reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for NVAX?

6 equities research analysts have issued twelve-month price objectives for Novavax's shares. Their forecasts range from $161.00 to $294.00. On average, they anticipate Novavax's share price to reach $249.60 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts' price targets for Novavax
or view top-rated stocks among Wall Street analysts.

Who are Novavax's key executives?

Novavax's management team includes the following people:
  • Stanley C. Erck, President, Chief Executive Officer & Director
  • Richard Crowley, Chief Operating Officer & Executive Vice President
  • James Patrick Kelly, Chief Financial Officer, Treasurer & Executive VP
  • Gregory M. Glenn, President-Research & Development (LinkedIn Profile)
  • Filip Dubovsky, Chief Medical Officer & Executive Vice President

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

Who are some of Novavax's key competitors?

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.96%), RA Capital Management L.P. (3.44%), State Street Corp (2.27%), Susquehanna International Group LLP (0.00%), Citadel Advisors LLC (0.00%) and Franklin Resources Inc. (1.48%). Company insiders that own Novavax stock include Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax
.

Which major investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., RA Capital Management L.P., Price T Rowe Associates Inc. MD, Northern Trust Corp, IMC Chicago LLC, Geode Capital Management LLC, Franklin Resources Inc., and Creative Planning. Company insiders that have sold Novavax company stock in the last year include Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, and Stanley C Erck.
View insider buying and selling activity for Novavax
or view top insider-selling stocks.

Which major investors are buying Novavax stock?

NVAX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Simplex Trading LLC, PEAK6 Investments LLC, State Street Corp, Sumitomo Mitsui Trust Holdings Inc., Legal & General Group Plc, Swiss National Bank, and Ikarian Capital LLC. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax
or or view top insider-buying stocks.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $226.71.

How much money does Novavax make?

Novavax has a market capitalization of $16.89 billion and generates $475.60 million in revenue each year. The biopharmaceutical company earns $-418,260,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis.

How many employees does Novavax have?

Novavax employs 791 workers across the globe.

When was Novavax founded?

Novavax was founded in 1987.

What is Novavax's official website?

The official website for Novavax is www.novavax.com.

Where are Novavax's headquarters?

Novavax is headquartered at 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at (240) 268-2000 or via email at [email protected].


This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.